Annotation Detail

Information
Associated Genes
MET
Associated Variants
MET EXON 14 SKIPPING MUTATION
MET EXON 14 SKIPPING MUTATION
Associated Disease
lung adenocarcinoma
Source Database
CIViC Evidence
Description
In a never-smoking metastatic lung adenocarcinoma patient harboring a MET splice site mutation (c.2887-18_2887-7del12) treated with crizotinib monotherapy, was associated with a response as evident by the reduced size of tumors. Prior to identification of the MET splice site mutation, the patient was treated with stereotactic radiotherapy, palliative radiation, and a single cycle of pemetrexed; subsequently, the patient was treated with crizotinib, but progressed at 8 weeks of treatment.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/4786
Gene URL
https://civic.genome.wustl.edu/links/genes/52
Variant URL
https://civic.genome.wustl.edu/links/variants/324
Rating
1
Evidence Type
Predictive
Disease
Lung Adenocarcinoma
Evidence Direction
Supports
Drug
Crizotinib
Evidence Level
C
Clinical Significance
Sensitivity/Response
Pubmed
25769807
Drugs
Drug NameSensitivitySupported
CrizotinibSensitivitytrue